This review provides a critical overview of the current potential of nanotechnology to solve problems associated with overcoming biological barriers to deliver novel cancer therapies, including small cytotoxic molecules and biological drugs such as RNA or mAbs. Nanodelivery strategies, including active and passive targeting, are benefitting from significant progress in drug discovery, molecular biology, and biomaterials advances.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Recent Comments